GKB Ophthalmics (NSE:GKB) Current Deferred Revenue: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:GKB GKB Ophthalmics Ltd NSE:GKB
44 GF Score
Price ₹63.00
GF Value ₹126.38
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is GKB Ophthalmics Current Deferred Revenue?

GKB Ophthalmics NSE:GKB 44 Current Deferred Revenue is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:GKB with a GF Score™ of 44/100 and a GF Value™ of ₹126.38 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

GKB Ophthalmics's current deferred revenue for the quarter that ended in Jun. 2026 was ₹0 Mil.

GKB Ophthalmics Current Deferred Revenue Related Terms

GKB Ophthalmics Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for GKB Ophthalmics's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GKB Ophthalmics Current Deferred Revenue Chart

GKB Ophthalmics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GKB Ophthalmics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:GKB
44GF Score
GKB Ophthalmics Ltd NSE:GKB
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of ₹0 Mil mean?
GKB Ophthalmics (NSE:GKB) has a Current Deferred Revenue of ₹0 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on GKB Ophthalmics and its competitors.
Is GKB Ophthalmics' Current Deferred Revenue too high?
GKB Ophthalmics' current Current Deferred Revenue is ₹0 Mil. Overall, GKB Ophthalmics has a GF Score™ of 44/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GKB Ophthalmics' Current Deferred Revenue compare to ISRG and BDX?
GKB Ophthalmics' Current Deferred Revenue of ₹0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Devices & Instruments company?
A good Current Deferred Revenue depends on the Medical Devices & Instruments industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on GKB Ophthalmics and its competitors. GKB Ophthalmics's current Current Deferred Revenue is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GKB Ophthalmics stock overvalued right now?
Based on GuruFocus' analysis, GKB Ophthalmics (NSE:GKB) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹126.38, compared to a current price of ₹63.00 — trading 50.2% below its estimated fair value. The current Current Deferred Revenue is ₹0 Mil. GKB Ophthalmics' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For GKB Ophthalmics (NSE:GKB), the current Current Deferred Revenue is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GKB Ophthalmics (NSE:GKB) Overvalued in 2026?

Based on GuruFocus' analysis, GKB Ophthalmics stock appears to be undervalued. The current stock price of ₹63.00 is trading 50.2% below its estimated GF Value™ of ₹126.38. GuruFocus considers GKB Ophthalmics to be Significantly Undervalued.

Key valuation signals for NSE:GKB:

  • Current Deferred Revenue: ₹0 Mil
  • GF Value™: ₹126.38 vs. price of ₹63.00 (50.2% below fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the NSE:GKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GKB Ophthalmics Business Description

Other Exchanges 533212:India
Address 16-A, Tivim Industrial Estate, Mapusa, GA, IND, 403 526
GKB Ophthalmics Ltd is an India-based company engaged in manufacturing and exporting ophthalmics lenses. It manufactures glass and plastic lenses both semi-finished and finished forms. The other products of the company include Organic lenses, Glass moulds, and Bifocal moulds. The company sells its products in India and also exports globally. Geographically, the majority of its revenue is generated from outside of India.
44GF Score

Get the complete analysis for NSE:GKB

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹63.00
Price
₹126.38
GF Value